Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Pekings Sanktionsliste: Wie stark trifft es die Aktien von Rheinmetall, HENSOLDT, RENK und TKMS? (Finanzen.net) +++ RENK Aktie +3,06%

Gewinn & Umsatz News zur TEVA Aktie

 >TEVA Aktienkurs 
27.4 EUR    +1.1%    (TradegateBSX)
Ask: 27.8 EUR / 1000 Stück
Bid: 27.5 EUR / 1000 Stück
Tagesumsatz: 7304 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
TEVA Aktie über LYNX handeln
>TEVA Performance
1 Woche: -4,6%
1 Monat: -9,6%
3 Monate: +4,2%
6 Monate: 0%
1 Jahr: +94,3%
laufendes Jahr: +1,1%
>TEVA Aktie
Name:  TEVA PHARMACEUTICAL INDUSTRIES ADR
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US8816242098 / 883035
Symbol/ Ticker:  TEV (Frankfurt) / TEVA (NYSE)
Kürzel:  FRA:TEV, ETR:TEV, TEV:GR, NYSE:TEVA
Index:  -
Webseite:  https://www.tevapharm.com..
Profil:  Teva Pharmaceutical Industries Ltd. ADR represents shares of an Israeli-based global pharmaceutical company focused on developing, manufacturing, and marketing medicines across multiple therapeutic areas. Teva is widely recognized for its large portf..
>Volltext..
Marktkapitalisierung:  31844.54 Mio. EUR
Unternehmenswert:  43402.07 Mio. EUR
Umsatz:  15381 Mio. EUR
EBITDA:  4454.91 Mio. EUR
Nettogewinn:  1381.35 Mio. EUR
Gewinn je Aktie:  1.2 EUR
Schulden:  14836.99 Mio. EUR
Liquide Mittel:  3282.97 Mio. EUR
Operativer Cashflow:  868.51 Mio. EUR
Bargeldquote:  0.28
Umsatzwachstum:  5.76%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Div. Historie:  27.11.17 - 0.07293€
25.08.17 - 0.07293€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  TEVA
Letzte Datenerhebung:  27.07.26
>TEVA Kennzahlen
Aktien/ Unternehmen:
Aktien: 1164.64 Mio. St.
Frei handelbar: 99.99%
Leerverk. Aktien: 2.81%
Rückkaufquote: -
Mitarbeiter: 33346
Umsatz/Mitarb.: 0.46 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 33.39%
Bewertung:
KGV: 23.26
KGV lG: 15.48
KUV: 2.03
KBV: 4.43
PEG-Ratio: -
EV/EBITDA: 9.74
Rentabilität:
Bruttomarge: 52.19%
Gewinnmarge: 8.98%
Operative Marge: 23.22%
Managementeffizenz:
Gesamtkaprendite: 4.01%
Eigenkaprendite: 21.73%
 >TEVA Anleihen 
>TEVA Peer Group
Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Onkologie/ Krebs- Behandlung
 
07.07.26 - 17:00
 Teva reports positive skin treatment drug results (Globes)
 
The Israeli company reported in the study that patients showed improvements in skin pigmentation with vitiligo....
29.04.26 - 14:30
 Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets (AFX)
 
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries (TEVA) said, for 2026, non-GAAP operating income is now projected in a range of $3.80 - $4.0 billion, revised from $4.55 - $4.8 billion stand......
29.04.26 - 14:18
 Teva Rises After Sales Top Estimates on Shift to Branded Drugs (Bloomberg)
 
Generic drug manufacturer Teva Pharmaceuticals Inc. beat Wall Street estimates on Wednesday for the first quarter on demand for its branded medications....
17.02.26 - 15:42
 Sanofi, Teva Report Positive Phase 2b Results For Duvakitug (AFX)
 
PARIS (dpa-AFX) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerat......
28.01.26 - 14:12
 Teva sees lower revenue and profit in 2026 (Globes)
 
After three consecutive years of growth, the Israeli pharmaceutical company predicts a small decline this year....
28.01.26 - 13:54
 Teva Slumps as 2026 Revenue Outlook Falls Short of Expectations (Bloomberg)
 
Teva Pharmaceuticals Inc. fell Wednesday after its 2026 revenue forecast was weaker than Wall Street expected....
28.01.26 - 13:54
 Teva Pharmaceutical Turns To Profit In Q4, Announces FY26 Outlook (AFX)
 
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributa......
06.12.25 - 16:42
 Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue (24/7 Wall St.)
 
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue The post Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue appeared first on 24/7 Wall St.....
05.11.25 - 21:24
 Teva Hits Highest Since 2018 as 3Q Revenue Beats Estimates (Bloomberg)
 
Teva Pharmaceutical CEO Richard Francis speaks about 3Q earnings on Bloomberg BusinessWeek with Bloomberg's Katie Greifeld and Emily Graffeo.  (Source: Bloomberg)...
05.11.25 - 14:06
 Teva Surges After Push Into Branded Drugs Drives Sales Beat (Bloomberg)
 
Teva Pharmaceuticals Inc. surged after sales of branded medications topped expectations, showing that its strategy to expand into that drug category is working....
05.11.25 - 13:54
 Teva Pharma Boosts FY25 Adj. EPS Outlook As Q4 Results Top Estimates; Shares Up 9% (AFX)
 
PETAH TIKVA (dpa-AFX) - While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) raised its adjusted earnings guidance for the full-year 2025......
03.11.25 - 16:54
 Teva jumps ahead of Q3 results (Globes)
 
Since the stock’s low-point in 2025 in April, the Israeli pharmaceutical company’s share price has risen over 60%....
30.07.25 - 14:06
 Teva again raises profit guidance (Globes)
 
The Israeli pharmaceutical company beat the analysts on profit but missed on revenue in the second quarter of 2025....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Aus einem Weisen wird man nicht klug. - Elazar Benyoetz
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!